CD40LG and COVID-19: A trial, recently registered in ClinicalTrial.gov (NCT04316728), will specifically address this issue by investigating the monitoring of seroconversion of COVID-19 IgG/IgM in healthy subjects who may develop COVID-19–related symptoms.